X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
brivaracetam (167) 167
epilepsy (141) 141
index medicus (130) 130
humans (108) 108
clinical neurology (89) 89
double-blind (86) 86
partial-onset seizures (80) 80
levetiracetam (77) 77
antiepileptic drugs (75) 75
adjunctive brivaracetam (72) 72
anticonvulsants - therapeutic use (70) 70
pharmacology & pharmacy (67) 67
seizures (64) 64
male (53) 53
animals (51) 51
placebo-controlled trial (49) 49
synaptic vesicle protein (48) 48
adverse event profile (47) 47
epilepsy - drug therapy (47) 47
sv2a ligand (46) 46
pyrrolidinones - therapeutic use (45) 45
anticonvulsants (43) 43
efficacy (43) 43
pharmacokinetics (43) 43
adult (42) 42
adults (42) 42
anticonvulsants - adverse effects (42) 42
anticonvulsants - pharmacology (39) 39
neurology (36) 36
analysis (35) 35
female (34) 34
middle aged (34) 34
phase-iii (34) 34
dose-response relationship, drug (32) 32
cns pharmacodynamics (31) 31
tolerability (31) 31
treatment outcome (31) 31
neurosciences (30) 30
pyrrolidinones - adverse effects (29) 29
young adult (29) 29
safety (28) 28
sv2a (27) 27
adolescent (26) 26
epilepsies, partial - drug therapy (26) 26
pyrrolidinones - administration & dosage (25) 25
anticonvulsants - administration & dosage (24) 24
anticonvulsants - pharmacokinetics (24) 24
drugs (24) 24
lacosamide (24) 24
clinical trials (23) 23
drug therapy (23) 23
pyrrolidinones - pharmacology (23) 23
antiepileptic agents (22) 22
antiepileptic drug (21) 21
care and treatment (21) 21
double-blind method (20) 20
eslicarbazepine acetate (20) 20
perampanel (20) 20
pyrrolidinones - pharmacokinetics (20) 20
aged (18) 18
psychiatry (18) 18
status epilepticus (18) 18
carbamazepine (17) 17
clinical trials as topic (17) 17
drug therapy, combination (17) 17
medical research (17) 17
seizures - drug therapy (17) 17
convulsions & seizures (16) 16
rats (16) 16
patients (15) 15
piracetam - analogs & derivatives (15) 15
seizure (15) 15
synaptic vesicle protein 2a (15) 15
drug interactions (14) 14
etiracetam (14) 14
focal epilepsy (14) 14
complications and side effects (13) 13
drug dosages (13) 13
medicine & public health (13) 13
pharmacology (13) 13
studies (13) 13
brain (12) 12
medicine, experimental (12) 12
mice (12) 12
refractory epilepsy (12) 12
topiramate (12) 12
disease models, animal (11) 11
drug development (11) 11
drug-resistant epilepsy (11) 11
eslicarbazepine (11) 11
research (11) 11
behavioral sciences (10) 10
binding-site (10) 10
ligands (10) 10
pregabalin (10) 10
valproic acid (10) 10
adult patients (9) 9
binding (9) 9
dosage and administration (9) 9
lamotrigine (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medical Letter on Drugs and Therapeutics, ISSN 0025-732X, 07/2017, Volume 59, Issue 1526, pp. 121 - 123
Journal Article
DRUG METABOLISM AND DISPOSITION, ISSN 0090-9556, 01/2008, Volume 36, Issue 1, pp. 36 - 45
This study was designed to investigate the human absorption, disposition, and mass balance of C-14-brivaracetam, a novel high affinity SV2A ligand with potent... 
SINGLE | UCB-34714 | BRIVARACETAM | PHARMACOLOGY & PHARMACY
Journal Article
Epilepsy Research, ISSN 0920-1211, 01/2020, Volume 159, p. 106236
Brivaracetam (BRV) was recently introduced for the treatment of patients with focal epilepsy. BRV undergoes relatively few interactions, but one of them leads... 
Tolerability | Brivaracetam | Carbamazepine epoxide | Interaction | Carbamazepine
Journal Article
Seizure: European Journal of Epilepsy, ISSN 1059-1311, 07/2019, Volume 69, pp. 198 - 203
The rate of brivaracetam-related behavioural adverse events is a current focus of discussion. This study aims to assess the effect of brivaracetam on anger... 
Psychiatric adverse events | Aggressive behaviour | Brivaracetam | Antiepileptic drugs | Epilepsy | Behavioural disorders | SV2A LIGAND | EFFICACY | SAFETY | 3-PHASE III | NEUROSCIENCES | CLINICAL NEUROLOGY | PROFILE | TOLERABILITY | ADJUNCTIVE BRIVARACETAM | ONSET | LEVETIRACETAM
Journal Article
Epilepsy & Behavior, ISSN 1525-5050, 01/2020, Volume 102, p. 106657
The aim of this study was to evaluate the efficacy, tolerability, and retention of brivaracetam (BRV) in genetic generalized epilepsy (GGE) in real-life... 
Refractory | Genetic generalized epilepsy | Seizure | Brivaracetam | SV2A
Journal Article
NEUROPSYCHIATRIC DISEASE AND TREATMENT, ISSN 1178-2021, 2019, Volume 15, pp. 2587 - 2600
Journal Article
Epilepsy Research, ISSN 0920-1211, 09/2018, Volume 145, pp. 55 - 62
To assess the association, if any, between brivaracetam (BRV)-induced elevated carbamazepine-10,11-epoxide (CBZ-E) and toxicity and efficacy in patients with... 
Efficacy | Brivaracetam | Safety | Epilepsy | Carbamazepine-10,11-epoxide | ADULT PATIENTS | EPILEPTIC PATIENTS | CLINICAL NEUROLOGY | IN-VITRO | 10,11-EPOXIDE | PRESCRIPTION PATTERNS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ADJUNCTIVE BRIVARACETAM | ANTIEPILEPTIC DRUGS | Medicine, Experimental | Medical research | Poisoning | Seizures (Medicine) | Carbamazepine | Index Medicus
Journal Article
Organic and Biomolecular Chemistry, ISSN 1477-0520, 11/2016, Volume 14, Issue 43, pp. 1134 - 1156
The γ-lactam moiety is present in a large number of natural and non-natural biologically active compounds. The range of biological activities covered by these... 
CHEMISTRY, ORGANIC | 4,5-DISUBSTITUTED CIS-PYRROLIDINONES | FUSARIUM TOXIN EQUISETIN | STEREOSELECTIVE-SYNTHESIS | PART 2 | ADJUNCTIVE BRIVARACETAM | ENANTIOSELECTIVE TOTAL-SYNTHESIS | ASYMMETRIC TOTAL-SYNTHESIS | REDUCTIVE CYCLIZATION | STEREOCONTROLLED SYNTHESIS | STRUCTURE-BASED DESIGN
Journal Article
Seizure: European Journal of Epilepsy, ISSN 1059-1311, 04/2019, Volume 67, pp. 38 - 39
Journal Article
Acta Neurologica Scandinavica, ISSN 0001-6314, 09/2018, Volume 138, Issue 3, pp. 195 - 202
Journal Article
Expert Review of Clinical Pharmacology, ISSN 1751-2433, 05/2016, Volume 9, Issue 5, pp. 637 - 645
Brivaracetam is the latest approved antiepileptic drug in focal epilepsy and exhibits high affinity as SV2A-ligand. More than two thousand patients have... 
epilepsy | myoclonus | seizure | Brivaracetam | SV2A LIGAND | SYNAPTIC VESICLE PROTEIN | PARTIAL-ONSET SEIZURES | CNS PHARMACODYNAMICS | DRUG-RESISTANT EPILEPSY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | ADJUNCTIVE BRIVARACETAM | ADVERSE EVENT PROFILE
Journal Article
Frontiers in Neurology, ISSN 1664-2295, 02/2018, Volume 9
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2018, Volume 61, Issue 16, pp. 7004 - 7031
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities provide insight... 
POLY(ADP-RIBOSE) POLYMERASE | OPHTHALMIC SOLUTION | CHEMISTRY, MEDICINAL | ASYMMETRIC-SYNTHESIS | EFFICIENT SYNTHESIS | BRIVARACETAM | 1-DEOXYGALACTONOJIRIMYCIN | INHIBITOR | LIFITEGRAST | LFA-1/ICAM-1 ANTAGONIST | DISCOVERY
Journal Article
Epilepsy & Behavior, ISSN 1525-5050, 12/2019, Volume 101, p. 106541
The new anticonvulsant brivaracetam is a levetiracetam analog which binds to the synaptic vesicle protein 2A, and inhibits excitatory neurotransmitters'... 
Jeavons syndrome | Drug-resistant epilepsy | Brivaracetam | Seizure exacerbation | Drop attacks
Journal Article